Avalo Therapeutics Inc (AVTX)
9.50
-0.14
(-1.45%)
USD |
NASDAQ |
May 17, 16:00
9.50
0.00 (0.00%)
After-Hours: 20:00
Avalo Therapeutics Research and Development Expense (Annual): 13.78M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 13.78M |
| December 31, 2022 | 31.31M |
| December 31, 2021 | 59.84M |
| December 31, 2020 | 32.19M |
| December 31, 2019 | 11.76M |
| December 31, 2018 | 5.787M |
| Date | Value |
|---|---|
| December 31, 2017 | 4.373M |
| December 31, 2016 | 10.15M |
| December 31, 2015 | 6.587M |
| December 31, 2014 | 12.24M |
| December 31, 2013 | 8.914M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
11.76M
Minimum
2019
59.84M
Maximum
2021
29.78M
Average
31.31M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Imunon Inc | 11.29M |
| iBio Inc | 10.33M |
| Kodiak Sciences Inc | 206.30M |
| Petros Pharmaceuticals Inc | 2.409M |
| Ocugen Inc | 39.57M |